ERBB2 and colorectal cancer: In the positive TAPUR cohorts, an objective response rate (ORR) of 29 % was observed in mutated colorectal cancer patients containing V600E/D/K/R variants treated with cobimetinib and vemurafenib, 3.6 % ORR was seen in NSCLC patients treated with palbociclib, 11 % ORR was reported in metastatic colorectal cancer patients receiving pembrolizumab, 21 % ORR was reported in metastatic breast cancer patients treated with pembrolizumab, and 25 % ORR was noticed in individuals with ERBB2 overexpressed or amplified colorectal cancer receiving trastuzumab and pertuzumab.